Amiodarone Hydrochloride

DRUG5 trials

Conditions

At Least 10 Points in Rassi Risk Score for DeathAtrial FibrillationChagas CardiomyopathyEsophageal CarcinomaNon-sustained Ventricular Tachycardiaacute ischemic stroke and atrial fibrillation (AF)

Phase 2

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

RecruitingNCT06067438

OHSU Knight Cancer InstituteAtrial Fibrillation, Esophageal Carcinoma

Start: 2024-06-21End: 2027-08-30Target: 90Updated: 2026-05-22

Phase 3

A Trial Testing Amiodarone in Chagas Cardiomiopathy

NCT03193749

Fundación Cardioinfantil Instituto de CardiologíaChagas Cardiomyopathy

Start: 2017-06-12End: 2020-12-31Target: 200Updated: 2017-06-21

Phase 4

Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

TerminatedNCT04594746

University of CalgaryAtrial Fibrillation

Start: 2022-02-03End: 2026-01-20Updated: 2026-02-05

Early treatment of Atrial fibrillation for Stroke prevention Trial in acute STROKE (EAST-STROKE)

RecruitingCTIS2025-521260-35-00

University Medical Center Hamburg-Eppendorfacute ischemic stroke and atrial fibrillation (AF)

Start: 2025-11-07Target: 1035Updated: 2025-10-28

Unknown Phase

Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death

NCT01722942

InCor Heart InstituteChagas Cardiomyopathy, Non-sustained Ventricular Tachycardia, At Least 10 Points in Rassi Risk Score for Death

Start: 2014-10-06End: 2022-07-31Target: 1100Updated: 2021-08-30

Related Papers

Amiodarone or Implantable Cardioverter-Defibrillator in Chagas Cardiomyopathy

JAMA Cardiology2024-10-0220 citations

CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial.

2013-10-1128 citations